Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
CVS posts first-half growth as CMA market probe continues
(Sharecast News) - UK veterinary service provider CVS Group reported an 11.4% increase in revenue in its interim results on Thursday, to £329.9m, with a like-for-like sales growth of 6%. The AIM-traded firm said its adjusted EBITDA for the six months ended 31 December was ahead 8.9% at £63m, maintaining an EBITDA margin of 19.1%, aligning with its ambitions for the full year.
Membership in its preventative healthcare scheme, the Healthy Pet Club, grew to 500,000, reflecting sustained demand for companion pet veterinary care services in the UK.
Operationally, CVS said it was focussed on executing its mergers and acquisitions strategy, notably entering the Australian veterinary services market with 13 small animal acquisitions.
The group also completed four small animal practice acquisitions in the UK during the period.
Capital expenditure remained disciplined, with investments in infrastructure totalling £17.2m.
Notably, Bristol Vet Specialists, a flagship multi-disciplinary referral hospital, opened in October, offering a range of specialised services.
CVS said it had also prioritised improving standards of veterinary care, launching a new clinical governance framework aimed at enhancing standards across the profession and increasing veterinarian employment by 8.4% compared to the previous year.
Looking ahead, CVS said it was confident in its outlook, despite macroeconomic uncertainties and inflationary pressures.
The group anticipated continued growth, and reaffirmed its commitment to strategic goals including further expansion through acquisitions in both the UK and Australia.
CVS said it was aiming to double adjusted EBITDA over a five-year period, and was continuing to support the Competition and Markets Authority (CMA) in its market review of veterinary services in the UK.
"Our interim results reflect the continued resilience of our business despite the challenging macroeconomic backdrop affecting household incomes and inflationary pressures seen across UK and Europe," said chief executive officer Richard Fairman.
"We continue to execute on the growth strategy outlined at our capital markets day in November 2022 and during the period entered the Australian veterinary market, with 13 practices acquired alongside a further four acquisitions in the UK.
"We extended our bank facilities in January so that, alongside our cash-generative business model, we have committed funds in place for the next four years to help fund our investment plans."
At 1241 GMT, shares in CVS Group were down 5.94% at 1,495.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.